Facebook
X
LinkedIn
Forward
Emerging Topics in Liver Disease Conference: Innovative Trends in Liver Health 2026 - Sept. 19, 2026
In-Person and Virtual attendance options are available.
Presented by the Sherrie and Alan Conover Center for Liver Disease & Transplantation at Houston Methodist
The epidemic of liver disease has become increasingly more common and poses complex problems regarding diagnosis and management. There are recent advances in the diagnosis and management of patients with liver disease. This CE activity has been designed to educate attendees about new developments in hepatology, and new approaches to management of liver diseases that can be readily integrated into their daily practice. A group of national experts, including several renowned guest faculty, will present new findings in a clinical context that will be beneficial in the multidisciplinary management of unique and complex liver disorders.
This activity will provide lecture format presentations, debate and panel discussions, Q&A sessions and case discussions.
FEES
| REGISTRATION TYPE | FEE |
|---|---|
| Physician (Houston Methodist) | $30 |
| Physician (Private physician located within the Greater Houston Area)* | $275 |
| Physician (Private physician located outside the Greater Houston Area) | $50 |
| Allied Health Care Professional (including Nurses) | $20 |
| Resident / Fellow / Student | Complimentary |
*In compliance with HM’s policy on Physician Non-Monetary Compensation regarding “Stark Law,” private physicians who reside and/or practice medicine within the Greater Houston Area are required to pay the full Fair Market Value registration fee.
Presenters, topics, program schedule, and credit is subject to change
Target Audience
This conference is designed for primary care physicians, internists, hepatologists, gastroenterologists, oncologists, nurses, nurse practitioners, and physician assistants and other health care providers.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Provide significant information regarding new and critical developments in portal hypertension.
- Identify emerging trends in the Metabolic Dysfunction Associated Fatty Liver Disease (MASLD) and determine the latest concepts in diagnosis and management.
- Explain innovations occurring in the management of liver diseases, including viral hepatitis.
- Discuss current new developments and treatment of liver cancers –an emerging epidemic.
Course summary
- 7.75 AMA PRA Category 1 Credit™
Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Houston Methodist designates this Live activity for a maximum of 7.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 7.75 Attendance
- 7.75 Nursing Contact Hours
Houston Methodist is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Houston Methodist will award up to 7.75 nursing professional development contact hours for this activity.
- 7.75 Transplant CoordinatorsThe American Board for Transplant Certification (ABTC) has assigned the following Continuing Education Points for Transplant Certification (CEPTCs) to the following Houston Methodist Transplant Center educational program: Emerging Topics in Liver Disease Conference: Innovative Trends in Liver Health 2026 - Sept. 19, 2026 | Fri, 05/22/2026 - 8:00am | 7.75 Category 1 CEPTCs
| 2026 Emerging Topics in Liver Disease & Transplantation | ||
| AGENDA | Saturday, September 19 | ||
| TIME | PRESENTATION | SPEAKER(S) |
| 7:00 AM | Registration & Breakfast | |
| 7:30 AM | Conference Welcome | Victor Ankoma-Sey, MD, FACP, FAASLD |
| 7:35 AM | Introductory Remarks | R. Mark Ghobrial, MD, PhD, FACS, FRCS (Ed) |
| Plenary Session I : Complications of Portal Hypertension: New Insights & Emerging Strategies Moderators: Tamneet Basra, MD, MD and Ashish Saharia, MD, Julie Corkrean, MBA, RN, CCTC | ||
| 7:40 AM | State-of-the-Art Lecture I Noninvasive Assessment of Portal Hypertension and Risk of Hepatic Decompensation | Mitchell Shiffman, MD |
| 8:10 AM | Sarcopenia in Cirrhosis: Diagnosis, Current Management Strategies, and Future Directions | Aldo J. Montano-Loza, MD |
| 8:40 AM | Hepatic Encephalopathy in 2026: Practical Approaches to Diagnosis and Management | Omar Mousa MBBS, MD |
| 9:10 AM | Hepatorenal Syndrome (HRS): Contemporary Diagnosis and Management Updates | Florence Wong, MD |
| 9:40 AM | Q&A and Discussion | |
| 9:55 AM | BREAK | |
| Plenary Session II: Obesity and Metabolic Dysfunction – Associated Steatotic Liver Disease (MASLD): What’s New in 2026? Moderators: Victor Ankoma-Sey, MD, David Victor, III, MD, and Constance Mobley, MD | ||
| 10:10 AM | Evolving Management of Obesity: Pharmacotherapy for Weight Loss: New Insights and Clinical Application | Samaneh Dowlatshahi, MD |
| 10:40 AM | State-of-the-Art Lecture II: MASLD in 2026: Current Standards and Future Therapeutic Options | Fernando Membreno, MD |
| 11:10 AM | Debate: GLP-1 Receptor Agonists vs. MASH-Specific Therapy: Which Strategy Holds Greater Promise for Patients With MASLD? PRO: GLP-1 Receptor Agonists Should Be the Preferred Therapeutic Strategy CON: MASH-Specific Therapy Remains Essential for Optimal Disease Management Rebuttal Discussion | PRO: Chukwuma Egwim, MD CON: David W. Victor III, MD |
| 11:40 AM | Q&A and Discussion | |
| 11:55 AM | LUNCH | |
| 11:55 AM | PRODUCT THEATRE (Presented in Boardroom) *Not certified for CE credit | |
| Plenary Session III: Current Innovations in Chronic Liver Disease and Transplantation Moderators: R. Mark Ghobrial, MD, Caroline Simon, MD & Andrea Duchini, MD | ||
| 12:55 PM | State-of-the-Art Lecture III Advances in the Management of Primary Biliary Cholangitis and Primary Sclerosing Cholangitis | Tamneet Basra, MD |
| 1:20 PM | Hepatitis Delta Virus (HDV) Infection: Current Evaluation and Evolving Management Strategies | Michelle Jones- Pauley, MD |
| 1:45 PM | Towards Chronic HCV Elimination by 2030: Barriers, Opportunities and Path forward in the United States and Globally | John W. Ward, MD |
| 2:10 PM | Advances in Organ Preservation: Machine Perfusion Strategies for Expanding the Donor Pool | Caroline Simon, MD |
| 2:35 PM | The Next Frontier: Eliminating Immunosuppression in Organ Transplantation | Stephanie Tsai, MD |
| 3:00 PM | Q&A and Discussion | |
| 3:15 PM | BREAK | |
| Plenary Session IV: Liver Cancer: Current Concepts and Future Directions Moderators: Maen Abdelrahim, MD, & Kirk Heyne, MD, Yee Lee Cheah, MD | ||
| 3:30 PM | Presidential Address Transplantation Oncology - Liver Transplantation for Cholangiocarcinoma and Colorectal Liver Metastases: Where Do we Stand ? | Wojciech G. Polak, MD, PhD |
| 3:55 PM | State-of-the-Art Lecture IV Molecular and Immune Biomarkers in Hepatocellular Carcinoma and Cholangiocarcinoma: Can They Guide Therapeutic Decision- Making? | Ghassan K. Abou-Alfa, MD, JD, MBA, PhD (hc) |
| 4:20 PM | Hepatocellular Carcinoma in the Pre- and Post-Transplant Setting: Current Management Approaches and Evolving Strategies | Maen Abdelrahim, MD |
| 4:45 PM | Q&A and Discussion | |
| 5:00 PM | Adjourn | |
In-Person attendance will be held in the Houston Methodist Research Institute (6670 Bertner Avenue, Houston, Texas 77030).
Virtual information will be provided to registered learners.
| COURSE DIRECTOR |
| Victor Ankoma-Sey, MD, FACP, FAASLD |
| Director, Liver Transplant Program Sherrie and Alan Conover Center for Liver Disease & Transplantation Houston Methodist J.C. Walter Jr. Transplant Center Director, Liver Associates of Texas, PA |
Available Credit
- 7.75 AMA PRA Category 1 Credit™
Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Houston Methodist designates this Live activity for a maximum of 7.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 7.75 Attendance
- 7.75 Nursing Contact Hours
Houston Methodist is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Houston Methodist will award up to 7.75 nursing professional development contact hours for this activity.
- 7.75 Transplant CoordinatorsThe American Board for Transplant Certification (ABTC) has assigned the following Continuing Education Points for Transplant Certification (CEPTCs) to the following Houston Methodist Transplant Center educational program: Emerging Topics in Liver Disease Conference: Innovative Trends in Liver Health 2026 - Sept. 19, 2026 | Fri, 05/22/2026 - 8:00am | 7.75 Category 1 CEPTCs
Interested in exhibiting? Contact us for more information.
Exhibitors
We gratefully acknowledge the following companies for participating as exhibitors for this activity:
Ardelyx
AstraZeneca
Eisai
Gilead
Helio Genomics
HepQuant
Intra-Sana Laboratories
Ipsen
Keenova
Madrigal Pharmaceuticals
Mirum Pharmaceuticals
Orphalan
Takeda
Sponsors
We gratefully acknowledge the following companies for participating as exhibitors for this activity:
Break Sponsors: Madrigal Pharmaceuticals, Takeda
Lunch Sponsor: Gilead
Educational grants
We gratefully acknowledge the following companies for providing an educational grant to partially support this activity:
Madrigal
Price
FEES
| REGISTRATION TYPE | FEE |
|---|---|
| Physician (Houston Methodist) | $30 |
| Physician (Private physician located within the Greater Houston Area)* | $275 |
| Physician (Private physician located outside the Greater Houston Area) | $50 |
| Allied Health Care Professional (including Nurses) | $20 |
| Resident / Fellow / Student | Complimentary |
*In compliance with HM’s policy on Physician Non-Monetary Compensation regarding “Stark Law,” private physicians who reside and/or practice medicine within the Greater Houston Area are required to pay the full Fair Market Value registration fee.